You’ve likely heard the term “fat jabs” everywhere lately — from GP surgeries to daytime TV. As a certified personal trainer working with weight management clients across the UK since 2014, I’ve watched these medications transform how we approach obesity treatment. But there’s still enormous confusion about what they actually do inside your body. This guide cuts through the noise with straightforward, evidence-based information for 2026.
What Are “Fat Jabs” Exactly?
The popular term “fat jabs” refers to injectable medications that support weight loss by mimicking hormones your gut naturally produces. The two most widely used in the UK right now are semaglutide (brand name Wegovy or Ozempic) and tirzepatide (brand name Mounjaro). These belong to a drug class called GLP-1 receptor agonists — or dual GIP/GLP-1 agonists in tirzepatide’s case.
The NHS semaglutide guidance confirms these medications work primarily by slowing gastric emptying and reducing appetite signals in the brain, helping people feel fuller for longer on smaller amounts of food.
How They Work Inside Your Body
When you inject one of these medications once weekly, it binds to GLP-1 receptors throughout your digestive system and brain. Here’s the simplified cascade of events:
- Appetite suppression: The hypothalamus receives signals that reduce hunger cravings, particularly for high-calorie foods.
- Slower digestion: Food stays in your stomach longer, extending feelings of fullness after meals.
- Blood sugar regulation: Insulin release improves, reducing energy crashes that trigger snacking.
- Reduced food noise: Many patients describe a quieting of constant thoughts about food — something clinical trials have consistently documented.
The British Dietetic Association emphasises that these medications work most effectively when combined with dietary changes and increased physical activity — they are not a standalone solution.
Semaglutide vs Tirzepatide: 2026 Comparison
| Feature | Semaglutide (Wegovy) | Tirzepatide (Mounjaro) |
|---|---|---|
| Mechanism | GLP-1 agonist | Dual GIP/GLP-1 agonist |
| Average weight loss | ~15% body weight | ~20–22% body weight |
| NHS availability | Yes (specialist referral) | Yes (expanding 2026) |
| Private monthly cost | £150–£250 | £175–£280 |
| Common side effects | Nausea, fatigue, constipation | Nausea, diarrhoea, reduced appetite |
| Injection frequency | Once weekly | Once weekly |
Who Qualifies in the UK?
NHS eligibility typically requires a BMI of 35 or above alongside a weight-related health condition, or a BMI of 40 and above without additional conditions. Private clinics often work with a lower threshold of BMI 30+. Your GP remains your first point of contact for NHS routes, with referrals to specialist weight management services.
💬 From Sarah’s Client Files — Real
Sarah MitchellSarah Mitchell is a certified personal trainer (Level 3 REPS, OriGym) and wellness researcher based in Manchester. With 8+ years working with UK clients on home fitness, weight management, and supplement guidance, Sarah tests every product she recommends. She holds qualifications in nutrition coaching and writes only from direct experience. No affiliate bias — just honest UK fitness advice.You Might Also Like
